We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Cardiovascular Benefit of Merck’s Vytorin Unreliable, FDA Advisors Say
Cardiovascular Benefit of Merck’s Vytorin Unreliable, FDA Advisors Say
Despite a vast, “herculean feat” to obtain clinical trial data, the effect of Merck’s lipid-lowering Vytorin on cardiovascular health was just too small — with worrying holes in data that could hinder any proof of clinical meaningfulness, FDA advisors said.